Immunoprecise Antibodies Stock Buy Hold or Sell Recommendation
| IPA Stock | USD 1.22 0.03 2.40% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Immunoprecise Antibodies is 'Strong Sell'. Macroaxis provides Immunoprecise Antibodies buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding IPA positions. The advice algorithm takes into account all of Immunoprecise Antibodies' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Immunoprecise Antibodies' buy or sell advice are summarized below:
Real Value 2.9 | Target Price 7.99 | Hype Value 1.24 | Market Value 1.22 | Naive Value 1.25 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Immunoprecise Antibodies given historical horizon and risk tolerance towards Immunoprecise Antibodies. When Macroaxis issues a 'buy' or 'sell' recommendation for Immunoprecise Antibodies, the advice is generated through an automated system that utilizes algorithms and statistical models.
Immunoprecise |
Execute Immunoprecise Antibodies Buy or Sell Advice
The Immunoprecise recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Immunoprecise Antibodies. Macroaxis does not own or have any residual interests in Immunoprecise Antibodies or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Immunoprecise Antibodies' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunoprecise Antibodies Trading Alerts and Improvement Suggestions
| Immunoprecise Antibodies generated a negative expected return over the last 90 days | |
| Immunoprecise Antibodies has high historical volatility and very poor performance | |
| Immunoprecise Antibodies may become a speculative penny stock | |
| Immunoprecise Antibodies has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 20.66 M. Reported Net Loss for the year was (26.56 M) with profit before taxes, overhead, and interest of 11.56 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (19.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77. | |
| Immunoprecise Antibodies has a frail financial position based on the latest SEC disclosures | |
| Roughly 14.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results |
Immunoprecise Antibodies Returns Distribution Density
The distribution of Immunoprecise Antibodies' historical returns is an attempt to chart the uncertainty of Immunoprecise Antibodies' future price movements. The chart of the probability distribution of Immunoprecise Antibodies daily returns describes the distribution of returns around its average expected value. We use Immunoprecise Antibodies price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Immunoprecise Antibodies returns is essential to provide solid investment advice for Immunoprecise Antibodies.
| Mean Return | -0.13 | Value At Risk | -8.3 | Potential Upside | 12.14 | Standard Deviation | 5.83 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Immunoprecise Antibodies historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Immunoprecise Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Immunoprecise Antibodies is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immunoprecise Antibodies backward and forwards among themselves. Immunoprecise Antibodies' institutional investor refers to the entity that pools money to purchase Immunoprecise Antibodies' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Rathbone Brothers Plc | 2023-12-31 | 14 K | Citadel Advisors Llc | 2023-09-30 | 12.4 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 12.2 K | Ubs Group Ag | 2023-12-31 | 10.7 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 10.5 K | Mariner Wealth Advisors, Llc | 2023-12-31 | 10 K | Group One Trading, Lp | 2023-12-31 | 3.8 K | Royal Bank Of Canada | 2023-12-31 | 3.1 K | Simplex Trading, Llc | 2023-12-31 | 2.7 K | Ingalls & Snyder Llc | 2023-12-31 | 1.3 M | Northern Trust Corp | 2023-12-31 | 60.9 K |
Immunoprecise Antibodies Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (2.8M) | 39.1M | (11.8M) | (21.7M) | (24.9M) | (23.7M) | |
| Free Cash Flow | (2.0M) | (2.0M) | (11.2M) | (21.3M) | (19.2M) | (18.2M) | |
| Depreciation | 3.4M | 3.7M | 3.8M | 6.7M | 7.7M | 8.1M | |
| Other Non Cash Items | 982.1K | 1.4M | (310K) | 2.3M | 2.6M | 2.8M | |
| Capital Expenditures | 575.6K | 1.4M | 1.3M | 1.5M | 1.7M | 1.8M | |
| Net Income | (4.9M) | (7.3M) | (16.7M) | (26.6M) | (23.9M) | (22.7M) | |
| End Period Cash Flow | 2.7M | 41.8M | 30.0M | 8.4M | 9.6M | 10.1M | |
| Change To Inventory | (23.4K) | (316K) | (501K) | (185K) | (166.5K) | (174.8K) | |
| Investments | (1.6M) | (2.5M) | (5.2M) | (2.0M) | (1.8M) | (1.9M) | |
| Net Borrowings | (318.5K) | (772K) | (962K) | (1.3M) | (1.2M) | (1.1M) | |
| Change To Netincome | 1.3M | 4.0M | 2.4M | 3.3M | 3.8M | 2.9M |
Immunoprecise Antibodies Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Immunoprecise Antibodies or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Immunoprecise Antibodies' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Immunoprecise stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.25 | |
β | Beta against NYSE Composite | 1.22 | |
σ | Overall volatility | 5.75 | |
Ir | Information ratio | -0.04 |
Immunoprecise Antibodies Volatility Alert
Immunoprecise Antibodies exhibits very low volatility with skewness of 1.55 and kurtosis of 3.64. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immunoprecise Antibodies' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immunoprecise Antibodies' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Immunoprecise Antibodies Fundamentals Vs Peers
Comparing Immunoprecise Antibodies' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Immunoprecise Antibodies' direct or indirect competition across all of the common fundamentals between Immunoprecise Antibodies and the related equities. This way, we can detect undervalued stocks with similar characteristics as Immunoprecise Antibodies or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Immunoprecise Antibodies' fundamental indicators could also be used in its relative valuation, which is a method of valuing Immunoprecise Antibodies by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Immunoprecise Antibodies to competition |
| Fundamentals | Immunoprecise Antibodies | Peer Average |
| Return On Equity | -0.26 | -0.31 |
| Return On Asset | -0.11 | -0.14 |
| Profit Margin | (0.60) % | (1.27) % |
| Operating Margin | (0.54) % | (5.51) % |
| Current Valuation | 40.29 M | 16.62 B |
| Shares Outstanding | 26.32 M | 571.82 M |
| Shares Owned By Insiders | 13.59 % | 10.09 % |
| Shares Owned By Institutions | 6.73 % | 39.21 % |
| Number Of Shares Shorted | 318.2 K | 4.71 M |
| Price To Book | 0.94 X | 9.51 X |
| Price To Sales | 1.51 X | 11.42 X |
| Revenue | 20.66 M | 9.43 B |
| Gross Profit | 11.56 M | 27.38 B |
| EBITDA | (21.26 M) | 3.9 B |
| Net Income | (26.56 M) | 570.98 M |
| Cash And Equivalents | 19.24 M | 2.7 B |
| Cash Per Share | 0.77 X | 5.01 X |
| Total Debt | 7.27 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 5.06 X | 2.16 X |
| Book Value Per Share | 1.89 X | 1.93 K |
| Cash Flow From Operations | (19.83 M) | 971.22 M |
| Short Ratio | 0.21 X | 4.00 X |
| Earnings Per Share | (0.47) X | 3.12 X |
| Target Price | 7.02 | |
| Number Of Employees | 102 | 18.84 K |
| Beta | 0.33 | -0.15 |
| Market Capitalization | 32.1 M | 19.03 B |
| Total Asset | 77.81 M | 29.47 B |
| Retained Earnings | (73.09 M) | 9.33 B |
| Working Capital | 10.87 M | 1.48 B |
| Net Asset | 77.81 M |
Immunoprecise Antibodies Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Immunoprecise . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Immunoprecise Antibodies Buy or Sell Advice
When is the right time to buy or sell Immunoprecise Antibodies? Buying financial instruments such as Immunoprecise Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 1.3M | 441K | 507.2K | 599.4K | Total Assets | 93.5M | 77.8M | 89.5M | 94.0M |
Use Investing Ideas to Build Portfolios
In addition to having Immunoprecise Antibodies in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Silver Thematic Idea Now
Silver
Companies involved in mining, production, and distribution of silver and silver goods. The Silver theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Silver Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Immunoprecise Antibodies Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.47) | Revenue Per Share 0.939 | Quarterly Revenue Growth 0.203 | Return On Assets (0.11) | Return On Equity (0.26) |
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.